Rapid depletion of B lymphocytes by ultra-low-dose rituximab delivered intrathecally

OBJECTIVE: We are conducting an open-label phase 1b study on the efficacy of intrathecal (IT) administration of rituximab, provided via an Ommaya reservoir, for the treatment of progressive multiple sclerosis (PMS). The objective of this initial study was to monitor B lymphocytes in peripheral blood...

Descripción completa

Detalles Bibliográficos
Autores principales: Svenningsson, Anders, Bergman, Joakim, Dring, Ann, Vågberg, Mattias, Birgander, Richard, Lindqvist, Thomas, Gilthorpe, Jonathan, Bergenheim, Tommy
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Lippincott Williams & Wilkins 2015
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4345631/
https://www.ncbi.nlm.nih.gov/pubmed/25745637
http://dx.doi.org/10.1212/NXI.0000000000000079

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4345631/
https://www.ncbi.nlm.nih.gov/pubmed/25745637
http://dx.doi.org/10.1212/NXI.0000000000000079

Ejemplares similares